Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M73.9Revenue (TTM) $M--Net Margin (%)--Altman Z-Score7.0
Enterprise Value $M-6.3EPS (TTM) $-2.7Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %--Quick Ratio17.6Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio17.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-40.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.5ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NVLS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVLSJulian Robertson 2015-09-30 Buy 1.13%$12.74 - $20.16
($16.43)
$ 4.78-71%New holding650,915
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVLS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVLS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Congleton JonPresident and CEO 2016-03-24Buy5,000$4.2213.27view
Congleton JonPresident and CEO 2016-03-22Buy5,000$4.389.13view
Congleton JonPresident and CEO 2015-12-11Buy5,000$8.1-40.99view
CONWAY ROBERT EDirector 2015-12-09Buy10,000$8.1-40.99view
Flynn James E 2015-06-23Buy250,000$14-65.86view
Hawkes Bay Master Investors (C10% Owner 2015-06-22Buy17,200$14.69-67.46view
Rock Springs Capital Managemen10% Owner 2015-06-22Buy200,000$14-65.86view
Hawkes Bay Master Investors (C10% Owner 2015-06-18Buy20,400$14.47-66.97view
Jennison Global Healthcare Mas10% Owner 2015-06-17Buy26,149$14-65.86view
GOTTLIEB ANDREWVP and General Counsel 2012-04-16Sell3,488$47.37-89.91view

Quarterly/Annual Reports about NVLS:

News about NVLS:

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nivalis Starts Dosing in Second Phase II Cystic Fibrosis Study May 17 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 16 2016
Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment... May 16 2016
Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment... May 16 2016
NIVALIS THERAPEUTICS, INC. Financials May 10 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 03 2016
Nivalis Therapeutics reports 1Q loss May 02 2016
Nivalis Therapeutics reports 1Q loss May 02 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 02 2016
Nivalis Therapeutics Reports First Quarter 2016 Financial Results May 02 2016
Nivalis Therapeutics Reports First Quarter 2016 Financial Results May 02 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Apr 22 2016
Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 22 2016
Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 22 2016
Nivalis Therapeutics Names David Rodman As Chief Medical Officer Apr 18 2016
Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President... Apr 18 2016
Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President... Apr 18 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 05 2016
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic... Apr 05 2016
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic... Apr 05 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)